View source for DISSABS / 1999:39502

AN   
     1999:39502  DISSABS   Order Number: AAIC701050 (not available for sale by
     UMI)
TI   
     EFFECTS ON ENERGY UTILIZATION AND EXPRESSION OF THE OBESITY GENE AND
     UNCOUPLING PROTEINS (UCP1 AND UCP2) BY NEW BETA-3 ADRENERGIC AGONIST IN
     RATS FED A CAFETERIA DIET
     EFECTOS EN LA UTILIZACION ENERGETICA Y EN LA EXPRESION DEL GEN DE LA
     OBESIDAD Y PROTEINAS DESACOPLANTES (UCP1 Y UCP3) DE UN NUEVO AGONISTA
     ADRENERGICO BETA3 EN UN MODELO DE OBESIDAD INDUCIDA CON UNA DIETA DE
     CAFETERIA
AU   
     BERRAONDO LOPEZ, BEATRIZ [DR.]
CS   
     UNIVERSIDAD DE NAVARRA (SPAIN) (5864)
SO   
     Dissertation Abstracts International, (1998) Vol. 60, No. 2C, p. 362.
     Order No.: AAIC701050 (not available for sale by UMI). 286 pages. FACULTY
     OF PHARMACY, UNIVERSITY OF NAVARRA, E-31080 PAMPLONA, SPAIN. 
DT   
     Dissertation
FS   
     DAI
LA   
     Spanish
AB   
         The $\beta3$-adrenergic agonists demonstrate major lipolytic,
     thermogenic and hypoglucaemic effects, and are potentially applicable in
     the treatment of obesity and diabetes. In this paper, we study the
     effects on energy consumption and the expression of the obesity gene and
     uncoupling proteins (UCP1 and UCP2) when the new $\beta3$-adrenergic
     agonist, Trecadrine, was administered for 35 days in a model of obesity
     induced by a cafeteria diet in female Wistar rats. Trecadrine (1 mg/kg)
     was given to the obese animals, and was found to reduce significantly
     their body weight and fat deposits as a result of an increase in lipolysis
     in the white and brown fat, as Trecadrine increases the activity of
     hormone-sensitive lipase and the consumption of oxygen in vitro in
     white fat. At the same time, the administration of Trecadrine (1 mg/kg) to
     obese rats produced an increase in thermogenesis, mediated by a rise in
     UCP1 expression in brown fat and UCP2 in the gastrocnemius muscle, the
     principal modulators of which seem to be the fatty acids which are
     mobilized when lipolysis is stimulated. However, UCP2 expression in the
     gastrocnemius was reduced in control rats treated with Trecadrine (1
     mg/kg), which suggests that the response was different in control animals
     from that in obese ones. Similarly, the administration of Trecadrine (1
     mg/kg) to obese animals brought down the plasma leptin levels and the
     amount of obesity gene which was expressed. In conclusion, Trecadrine
     could be of great interest for the treatment of obesity.
CC   
     0570 HEALTH SCIENCES, NUTRITION; 0307 BIOLOGY, MOLECULAR; 0433 BIOLOGY,
     ANIMAL PHYSIOLOGY